You searched for "stent"

672 results found

ERIC Conference, Together for 35 years: leading change in paediatric bowel and bladder health

ERIC, The Children’s Bowel & Bladder Charity, are back with their biennial conference. Healthcare professionals can expect talks on cutting-edge research, interactive workshops, practical demonstrations and much more. ERIC’s 2026 conference is a chance for professionals across the field of...

ABC (Action Bladder Cancer) UK Annual Nurses Education Day: Understanding Bladder Cancer and the Latest Developments

Action Bladder Cancer UK is holding its next annual Nurses’ Education Day for Urology Nurses and Clinical Nurse Specialists in Birmingham on Friday 5th September 2025. This is ABC UK’s fourth full day education event for nurses, following the success...

Recurrent UTI & Bladder Pain Syndrome: Understanding the Patient Journey and Improving Care

Join Bladder Health UK for a full‑day, evidence‑led study day bringing together leading clinicians, researchers and pelvic health specialists to explore the complexities of Recurrent UTI (RUTI) and Bladder Pain Syndrome (BPS). This event is designed for urologists, GPs, specialist...

RSM: The integrated pelvis: Advancing collaborative surgery in women’s pelvic care

This event will bring together leading clinicians to discuss the multidisciplinary management of complex pelvic disorders in women that span both the reproductive and gastrointestinal systems, highlighting advances in diagnosis, surgical techniques and coordinated care pathways. Featuring deep infiltrating endometriosis,...

The Re-humanising Revolution: Breaking the conspiracy of silence

Over the last few years, the mental and emotional wellbeing of those who work in medicine has come under scrutiny. The author introduces a new resource. Working in healthcare has always been stressful but never more so than today. In...

Quality Improvement – how to get involved?

The General Medical Council (GMC) requires all trainee doctors to carry out Quality Improvement (QI) as part of our annual appraisal process [1]. Exactly what QI projects are and how to get involved is less widely understood. Traditionally surgical trainees...

An MA in medical education – is it for you?

I have recently completed a three-year MA in medical education at the University of Winchester, which has been an edifying experience. The following article may appeal to readers who are considering such a venture. I have been a consultant for...

Defining adjuvant, consolidative, and salvage treatment after RP

The most common oncologic outcome following radical prostatectomy (RP) for localised prostate cancer is achieving undetectable prostate-specific antigen (PSA) levels (<0.1 ng/ml), indicating an absence of detectable disease. However, the landscape of RP is shifting as active surveillance becomes the...

Adrenal incidentalomas: what next?

An incidentaloma refers to an adrenal lesion >1cm discovered incidentally during radiologic examination. Identifying a malignant and / or functioning lesion is critical for management. However, as the majority of lesions are benign, the challenge is the identification of malignant...

Imaging and surveillance in sporadic renal angiomyolipoma: how and when to monitor effectively

Renal angiomyolipoma (AML) are benign tumours, accounting for approximately 2–3% of all renal neoplasms [1]. Seventy percent of renal AMLs are sporadic, and 20–30% are associated with genetic aetiology. They are composed of smooth muscle, blood vessels, and adipose tissue....

Renal oncocytoma: Diagnosis and surveillance strategy

Renal oncocytoma is one of the most common benign renal neoplasms, accounting for around 3–7% of all renal tumours, and up to 18% of all small renal masses (SRMs) measuring less than 4cm [1, 2]. Most oncocytomas are asymptomatic and...

Solifenacin and mirabegron are safe and effective in combination

Antimuscarinic agents remain the mainstay of medical management of bladder overactivity. Limited somewhat by their tolerability, the new agent mirabegron, a β3-adrenoreceptor agonist, has been approved as an alternative. There is little known however about the possible synergistic effects of...